Advertisement

Zystische Fibrose

  • J. Bargon
  • W. F. Caspary

Zusammenfassung

Die zystische Fibrose (CF), auch Mukoviszidose genannt, ist eine der häufigsten autosomal rezessiven Erbkrankheiten mit einer Carrierfrequenz von 1:25; jedes 2500. Neugeborene ist davon betroffen. Während vor 50 Jahren ein Großteil der Kinder im ersten Lebensjahr starb, liegt die durchschnittliche Lebenserwartung heute bei ca. 30 Jahren.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Balistreri WF (1997) Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 24:573–589PubMedCrossRefGoogle Scholar
  2. Bargon J, Sanders S, Caspary WF, Buhl R (1995) Therapie der zystischen Fibrose im Erwachsenenalter— Gegenwart und Zukunft. Pneumologie 49:573–583PubMedGoogle Scholar
  3. Bargon J, Stein J, Dietrich CF, Müller U, Caspary WF, Wagner TOF (1999) Gastrointestinale Komplikationen erwachsener Patienten mit zystischer Fibrose. Z Gastroenterol 37:739–749PubMedGoogle Scholar
  4. Colombo C, Battezzati PM (1996) Hepatobiliary manifestations of cystic fibrosis. Eur J Gastroenterol Hepatol 8:748–754PubMedGoogle Scholar
  5. Colombo C, Setchell KDR, Podda M, et. al., (1990) Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 117:482–489PubMedCrossRefGoogle Scholar
  6. Colombo C, Farrell P, Pencharz PB (1993) Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 82:562–565PubMedCrossRefGoogle Scholar
  7. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A and the Italian Group for the Study of Ursodeoxyeholic Acid in Cystic Fibrosis (1996) Ursodeoxyeholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology 23:1484–1490PubMedCrossRefGoogle Scholar
  8. Cotting J, Lentze MJ, Reichen J (1990) Effects of ursodeoxyeholic acid treatment on nutrition and life function in patients with cystic fibrosis and longstanding cholestasis. Gut 31:918–921PubMedCrossRefGoogle Scholar
  9. Lepage G, Paradis K, Lacaille F, et al., (1997) Ursodeoxyeholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr 130:52–58PubMedCrossRefGoogle Scholar
  10. Noble-Jamieson G, Valente J, Barnes ND, et al., (1994) Liver transplantation for hepatic cirrhosis in cystic fibrosis. Arch Dis Child 71:349–352PubMedCrossRefGoogle Scholar
  11. Smith LJ, Lacaille F, Lepage G, Ronco N, Lamarre A, Roy CC (1991) Taurine decreases fecal fatty acid and sterol excretion in cystic fibrosis. A randomized double-blind trial. Am J Dis Child 145:1401–1404PubMedGoogle Scholar
  12. Sokol RJ, Durie PR for the Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group (1999) Recommendations for the management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastroenterol Nutr 28:S1-S13Google Scholar
  13. Westaby D (1995) Liver and biliary disease im cystic fibrosis. In: Hodson ME, Geddes DM (Hrsg) Cystic fibrosis. Chapman and Hall Medical, London, S 281-293Google Scholar
  14. Yang Y, Raper SE, Cohn JA, Engelhardt JF, Wilson JM (1993) An approach for treating hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci USA 90:4601–4605PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • J. Bargon
  • W. F. Caspary

There are no affiliations available

Personalised recommendations